Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

CytomX Therapeutics Inc. (CTMX)

7.04   0.32 (4.76%) 10-21 16:00
Open: 6.73 Pre. Close: 6.72
High: 7.08 Low: 6.72
Volume: 410,781 Market Cap: 302M
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is engaged in developing antibody therapeutics based on probody technology platform.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.087 - 7.121 7.121 - 7.151
Low: 6.64 - 6.679 6.679 - 6.712
Close: 6.98 - 7.042 7.042 - 7.095

Technical analysis

as of: 2019-10-21 4:35:36 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 9.88     One year: 11.19
Support: Support1: 6.64    Support2: 5.52
Resistance: Resistance1: 8.46    Resistance2: 9.58
Pivot: 7.16
Moving Average: MA(5): 7.01     MA(20): 7.32
MA(100): 9.58     MA(250): 11.88
MACD: MACD(12,26): -0.48     Signal(9): -0.51
Stochastic oscillator: %K(14,3): 22.15     %D(3): 24.14
RSI: RSI(14): 39.77
52-week: High: 19.75  Low: 6.64  Change(%): -52.7
Average Vol(K): 3-Month: 39424  10-Days: 76538

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
CTMX has closed above bottom band by 39.5%. Bollinger Bands are 46.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to CTMX's normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Albireo Pharma Inc (NASDAQ: ALBO ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Assembly Biosciences Inc (NASDAQ: ASMB ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Calithera Biosciences Inc (NASDAQ: CALA ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Erytech Pharma SA (NASDAQ: ERYP ) Exagen Inc (NASDAQ: XGN ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gossamer Bio Inc (NASDAQ: GOSS ) Heat Biologics Inc (NASDAQ: HTBX ) Homology Medicines Inc (NASDAQ: FIXX ) INmune Bio Inc (NASDAQ: INMB ) Intellia Therapeutics Inc (NASDAQ: …

The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug
The following is a roundup of top developments in the biotech space over the last 24 hours. None of the NYSE or Nasdaq-listed biotech stocks hit 52-week highs on Tuesday. Down In The Dumps (Biotech stocks that hit 52-week lows Oct. 8.) ABIOMED, Inc. (NASDAQ: ABMD ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Albireo Pharma Inc (NASDAQ: ALBO ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BIOLASE Inc (NASDAQ: BIOL ) BioTelemetry Inc (NASDAQ: BEAT ) CELYAD SA/ADR (NASDAQ: CYAD ) Cerus Corporation (NASDAQ: CERS ) Chimerix Inc (NASDAQ: CMRX ) Clovis Oncology Inc (NASDAQ: CLVS ) (Goldman reiterated a Sell rating on the stock and cut the price target from $13 to $3.) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Endologix, Inc.

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 45.41
Shares Float (M) 41.20
% Held by Insiders 2.50
% Held by Institutions 86.29
Shares Short (K) 1820
Shares Short P. Month (K)

Stock Financials

EPS -2.200
Book Value (p.s.) 2.240
PEG Ratio 3.67
Profit Margin -158.05
Operating Margin -154.91
Return on Assets (ttm) -15.5
Return on Equity (ttm) -138.5
Qtrly Rev. Growth -57.8
Gross Profit (p.s.) 1.310
Sales Per Share
EBITDA (p.s.) -2.080
Qtrly Earnings Growth
Operating Cash Flow (M) -121.97
Levered Free Cash Flow (M) -36.00

Stock Valuations

P/E -3.20
P/E Growth Ratio 0.05
P/BV 3.14
P/S 229990224.00
P/CF -2.62

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.